Halted NIH Clinical Trials List Reveals Slashed Treatments for Cancer, COVID and Minority Health
| | | | | | | | | | | | | | | | | | | |

Halted NIH Clinical Trials List Reveals Slashed Treatments for Cancer, COVID and Minority Health

On Nov. 20, 2025, the National Institutes of Health (NIH) has canceled funding for at least 383 clinical…

Arrowhead Pharma Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
| | | |

Arrowhead Pharma Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

On Nov. 18, 2025, Arrowhead Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO…

NIH funding cuts have impacted more than 74,000 people enrolled in trials
| | | | | | | | | | | | | | | | | |

NIH funding cuts have impacted more than 74,000 people enrolled in trials

On Nov. 17, 2025, a JAMA published study found that more than 74,000 people have had their lives…

Prime Medicine Announces Breakthrough Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
| | |

Prime Medicine Announces Breakthrough Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

On May 19, 2025, Prime Medicine announced positive initial data from the first patient dosed in its ongoing…

HHS starts layoffs of thousands of workers across its agencies
| | | | | | | | | | | | | | | | | | | | |

HHS starts layoffs of thousands of workers across its agencies

On Apr. 1, 2025, layoff notices began arriving for thousands of employees of the sprawling U.S. Department of…

75% of U.S. scientists who answered Nature poll consider leaving
| | | | | | | | | | | | | | | | | |

75% of U.S. scientists who answered Nature poll consider leaving

On Mar. 27, 2025, a Nature survey of more than 1,200 scientists, three-quarters of the total respondents are…

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis
| |

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis

On Mar. 20, 2025, Alnylam Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approval of the supplemental…